Hodgkin's lymphoma Epidemiology

 

Key Highlights

 

• According to the National Organization of Rare Diseases (NORD), the majority of individuals with the adult form of Hodgkin’s disease are between 15 and 40 years of age at the time of diagnosis. A smaller number of individuals are affected after the age of 50. Hodgkin’s disease may also affect children. HL disease accounts for less than 1% of all cases of cancer in the United States.

 

• Hodgkin’s Lymphoma epidemiology is segmented as Total Hodgkin’s Lymphoma Incident Cases, Hodgkin’s Lymphoma Age-specific incident Cases, Hodgkin’s Lymphoma Gender-specific incident Cases, Hodgkin’s Lymphoma Incident Population of Relapsed/ Refractory form, and Treatable cases of Relapsed/ Refractory Hodgkin Lymphoma (R/R HL)] in the Hodgkin’s Lymphoma epidemiology report.

 

Request for Sample Report of Hodgkin’s Lymphoma Epidemiology

 

DelveInsight's ‘Hodgkin’s Lymphoma Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Hodgkin’s Lymphoma epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Geography Covered

• The United States
• EU4 (Germany, Spain, Italy, and France) and the United Kingdom
• Japan

 

Study Period: 2021-2034

 

Hodgkin’s Lymphoma Epidemiology: Disease Understanding

The DelveInsight’s Hodgkin’s Lymphoma epidemiology report gives a thorough understanding of Hodgkin’s Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. According to the National Organization for Rare Diseases, Hodgkin's disease comprises of a group of cancers, which are known as lymphoma. Lymphoma is a general term used to describe cancers that affect the lymphatic system, especially the lymph nodes. Tumors often form in the lymph nodes and/or the area around the nodes. 

 

With the help of some preliminary research, it has been seen that Hodgkin lymphoma can result due to multifactorial causes. These are due to an infectious agent, such as a virus (e.g., Epstein Barr Virus). Recent studies indicate that there may be a genetic susceptibility to Hodgkin’s disease in the young adult form of the disorder as well, environmental factors or immune system deficiencies may also play a role in the development of Hodgkin’s disease. Usually, the first sign of Hodgkin’s disease is a swollen lymph node. Two-thirds of the time, a lymph node in the neck is affected. Otherwise, lymph nodes in the armpits, chest, groin, or abdomen are affected. The disease may also spread to other lymph nodes, the area around the nodes, the spleen, liver, lungs, and bone marrow.

 

Hodgkin’s Lymphoma Diagnosis

A diagnosis of Hodgkin's disease is suspected, based upon a thorough clinical evaluation, a detailed patient history, and identification of characteristic findings (swollen lymph nodes, flu-like symptoms, etc.). A diagnosis may be confirmed by surgical removal and microscopic examination (biopsy) of tissue from a lymph node. The tissue is studied to determine whether particular cells called Reed-Sternberg cells are present.

Hodgkin’s Lymphoma Epidemiology 

The Hodgkin’s Lymphoma epidemiology section provides insights about historical and current Hodgkin’s Lymphoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

The disease epidemiology covered in the report provides historical as well as forecasted Hodgkin’s Lymphoma epidemiology scenario in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2021 to 2034.

 

Key Findings

 

• According to the National Organization of Rare Diseases (NORD), the majority of individuals with the adult form of Hodgkin’s disease are between 15 and 40 years of age at the time of diagnosis. A smaller number of individuals are affected after the age of 50. Hodgkin’s disease may also affect children. HL disease accounts for less than 1% of all cases of cancer in the United States.

 

• The disease epidemiology covered in the report provides historical as well as forecasted Hodgkin’s Lymphoma epidemiology [segmented as Total Incident Cases of Hodgkin’s Lymphoma, Age-specific incident Cases of Hodgkin’s Lymphoma, Gender-specific incident Cases of Hodgkin’s Lymphoma, Incident Population of Relapsed/ Refractory form of Hodgkin Lymphoma, and Treatable cases of Relapsed/ Refractory Hodgkin Lymphoma (R/R HL)] in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2021 to 2034.

 

Country Wise- Hodgkin’s Lymphoma Epidemiology

This section provides a glimpse of the Hodgkin’s Lymphoma epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

KOL- Views

To keep up with the current Hodgkin’s Lymphoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Hodgkin’s Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: Hodgkin's lymphoma Market
 

Scope of the Hodgkin’s Lymphoma Epidemiology Report

• The report covers the descriptive overview of Hodgkin’s Lymphoma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States,EU4 (Germany, Spain, Italy, and France) and the UK, and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Hodgkin’s Lymphoma 
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Hodgkin’s Lymphoma, Age-specific incident Cases of Hodgkin’s Lymphoma, Gender-specific incident Cases of Hodgkin’s Lymphoma, Incident Population of Relapsed/ Refractory form of Hodgkin Lymphoma, and Treatable cases of Relapsed/ Refractory Hodgkin Lymphoma (R/R HL)

 

Hodgkin’s Lymphoma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hodgkin’s Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hodgkin’s Lymphoma 
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Hodgkin’s Lymphoma Report Insights

• Patient Population
• Therapeutic Approaches

 

Hodgkin’s Lymphoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Hodgkin’s Lymphoma Epidemiology Segmentation

 

Hodgkin’s Lymphoma Report Assessment

• Disease Understanding
• Current Diagnosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

 

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Hodgkin’s Lymphoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What is the historical Hodgkin’s Lymphoma patient pool in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What would be the forecasted patient pool of Hodgkin’s Lymphoma in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Hodgkin’s Lymphoma?

• Out of all 7MM countries, which country would have the highest incident population of Hodgkin’s Lymphoma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Hodgkin’s Lymphoma Disease market
• To understand the future market competition in the Hodgkin’s Lymphoma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Hodgkin’s Lymphoma Disease in the US, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Hodgkin’s Lymphoma Disease market
• To understand the future market competition in the Hodgkin’s Lymphoma Disease market